文献速递预防保健、筛查与疫苗妇女保健慢病管理

阿片类药物处方与女性癌症筛查:一项全国性研究

Cancer Screening Among Women Prescribed Opioids: A National Study.
PubMed 文献 · Ann Fam Med · 2020-01-01

该研究基于2005-2015年美国医疗支出面板调查的全国代表性样本,纳入53,982名无癌症的成年女性,观察性分析阿片类药物处方与乳腺癌、宫颈癌和结直肠癌筛查的关系。结果显示,接受阿片类药物处方的女性调整后筛查几率更高,但进一步调整就诊次数后关联减弱。

要点

  • 接受阿片类药物处方的女性就诊次数更多,中位年就诊次数为5次对1次。
  • 未调整就诊次数时,阿片类药物处方与三种癌症筛查几率升高相关。
  • 调整就诊次数后,阿片类药物处方与癌症筛查的关联无统计学意义。

核心结论

  • 在全国代表性样本中,接受阿片类药物处方与较少接受推荐的癌症筛查无关。
  • 接受阿片类药物的女性调整后接受乳腺癌、宫颈癌和结直肠癌筛查的几率更高,但调整就诊次数后关联减弱。

研究设计与样本

  • 对2005-2015年医疗支出面板调查进行观察性分析,纳入53,982名≥18岁无癌症且有阿片类药物处方和预防保健服务数据的女性。

主要发现

  • 15.8%的参与者报告至少1次阿片类药物处方。
  • 接受阿片类药物处方的女性比未处方者更可能就诊,中位年就诊次数为5次对1次。
  • 未调整就诊次数时,乳腺癌筛查调整OR为1.26(95%CI 1.16-1.38),宫颈癌筛查为1.22(95%CI 1.13-1.33),结直肠癌筛查为1.22(95%CI 1.12-1.33)。
  • 调整就诊次数后,乳腺癌筛查调整OR为1.07(95%CI 0.98-1.18),宫颈癌筛查为1.01(95%CI 0.93-1.09),结直肠癌筛查为1.04(95%CI 0.95-1.14)。

临床怎么用

  • 全科医生不应因患者接受阿片类药物处方而降低对其癌症筛查的推荐。
  • 接受阿片类药物的女性就诊更频繁,可利用这些就诊机会落实乳腺癌、宫颈癌和结直肠癌筛查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prior work suggests that there are competing demands between addressing pain and other issues in primary care, potentially lessening delivery of evidence-based cancer screening. We assessed the association between opioid therapy and cancer screening among women in a nationally representative US sample. METHODS: We conducted an observational analysis of the 2005-2015 Medical Expenditure Panel Surveys. We included all women aged ≥18 years without cancer and with opioid prescription and preventive care services data. Logistic regression analyses examined associations between receipt of opioid prescription (any vs none) and receipt of breast, cervical, and colorectal cancer screenings. Analyses were adjusted for sociodemographic characteristics, health status, health conditions, and usual source of care, as well as health care utilization. RESULTS: Of 53,982 participants, 15.8% reported ≥1 opioid prescription. Compared with women not prescribed opioids, those prescribed opioids were more likely to visit their doctor (median number of visits per year = 5, vs 1). Without adjustment for number of visits, women prescribed opioids were more likely to receive all 3 cancer screenings; the adjusted odds ratio for breast cancer screening was 1.26 (95% CI, 1.16-1.38), that for cervical cancer screening was 1.22 (95% CI, 1.13-1.33), and that for colorectal cancer screening was 1.22 (95% CI, 1.12-1.33). With adjustment for number of visits, adjusted odds ratios decreased (breast 1.07 [95% CI, 0.98-1.18]; cervical 1.01 [95% CI, 0.93-1.09]; colorectal 1.04 [95% CI, 0.95-1.14]). CONCLUSIONS: In a nationally representative sample, receipt of opioid prescriptions was not associated with less recommended cancer screenings. Rather, women receiving opioids had greater adjusted odds of receiving breast, cervical, and colorectal cancer screening, although the associations were attenuated by adjusting for their more frequent office visits relative to women not receiving opioids.

来源:Ann Fam Med,查看原文。版权归原作者所有。

引用

  1. Agnoli A, Jerant A, Franks P, et al. Cancer Screening Among Women Prescribed Opioids: A National Study. Ann Fam Med. 2020. PMID: 31937534. doi:10.1370/afm.2489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。